Analysts Set Expectations for Vor Biopharma FY2028 Earnings

Key Points

• HC Wainwright has revised Vor Biopharma's FY2028 earnings per share estimate down to $0.03, lowering it from a previous estimate of $0.05, while maintaining a "Buy" rating with a target price of $3.00.
• Vor Biopharma's stock has experienced significant activity, trading up 5.3% to $2.09 recently, with a market capitalization of $264.04 million.
• Institutional investors hold a substantial 97.29% of the company's stock, reflecting strong interest from major investment firms like Goldman Sachs and Jane Street Group.

Vor Biopharma Inc. (NYSE:VOR - Free Report) - Analysts at HC Wainwright dropped their FY2028 earnings per share estimates for shares of Vor Biopharma in a research note issued to investors on Thursday, August 14th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of $0.03 per share for the year, down from their previous estimate of $0.05. HC Wainwright currently has a "Buy" rating and a $3.00 target price on the stock. The consensus estimate for Vor Biopharma's current full-year earnings is ($1.42) per share. HC Wainwright also issued estimates for Vor Biopharma's FY2029 earnings at $0.21 EPS.

Other research analysts also recently issued reports about the company. Jones Trading downgraded Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Baird R W downgraded Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Citizens Jmp cut Vor Biopharma from a "strong-buy" rating to a "hold" rating in a report on Friday, May 9th. Wedbush reissued an "outperform" rating on shares of Vor Biopharma in a report on Thursday, June 26th. Finally, JMP Securities reissued a "market perform" rating and set a $6.00 price target on shares of Vor Biopharma in a report on Friday, May 9th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $6.07.

Vor Biopharma Stock Up 5.3%

Shares of NYSE VOR traded up $0.11 during midday trading on Friday, hitting $2.09. 2,121,087 shares of the company's stock were exchanged, compared to its average volume of 8,025,602. Vor Biopharma has a 12 month low of $0.13 and a 12 month high of $3.29. The company's 50 day moving average price is $1.55 and its 200 day moving average price is $1.04. The firm has a market capitalization of $264.04 million, a PE ratio of -1.26 and a beta of 2.06.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd bought a new position in Vor Biopharma in the second quarter worth approximately $66,000. Goldman Sachs Group Inc. lifted its holdings in shares of Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after purchasing an additional 58,247 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Vor Biopharma in the first quarter valued at approximately $140,000. OMERS ADMINISTRATION Corp bought a new position in shares of Vor Biopharma in the first quarter valued at approximately $100,000. Finally, Money Concepts Capital Corp lifted its holdings in shares of Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after purchasing an additional 26,535 shares in the last quarter. Institutional investors own 97.29% of the company's stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.